Cancer detector Bard1 Life Sciences is still rocketing after the...

Cancer detector Bard1 Life Sciences is still rocketing after the company said it was adding breast cancer testing to its line-up.

After tripling on Tuesday, the stock (ASX:BD1) put on another 70 per cent this morning to hit an intraday high of 7.5c. That’s a gain of about 475 per cent compared to the 1.3c it was fetching yesterday.
These are the highest prices seen since Bard1 transformed from a gold miner EuroGold in 2016. Its share price rose as high as 27.7c in 2009.

Almost $20 million worth of shares had been traded this morning by 11.30am AEST.

The biotech has never achieved the giddy heights of its previous life as a gold explorer. But that may be about to change.

BARD1 has combined a biomarker and an algorithm into a blood test that can detect 6 per cent more cases of ovarian cancer than simply by using the algorithm.

It is now adapting that test to breast cancer. A lung cancer test is further back in the development process.
https://unauthorised investment advice/wp-content/uploads/2018/10/Screen-Shot-2018-10-24-at-10.58.15-am.png
Bard1 shares over the last week.
Bard1 says there is no blood test available on the market for screening or early detection of breast cancer.
The research shows that the BARD1 BC test has high diagnostic accuracy for detection of breast cancer and can accurately distinguish malignant breast cancer from benign lesions.

The idea is to make a non-invasive test for women who don’t have symptoms and aren’t high risk.